PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm

This triple-blind, placebo-controlled trial (n=30) will investigate the effects of a sub-hallucinogenic dose of psilocybin (5mg) in combination with Imagery Re-Scripting (ImRS) on cognitive processes and self-harm behaviour in young people aged 16–25.

The study, conducted by Imperial College London, aims to assess whether psilocybin enhances the effectiveness of ImRS by increasing tolerance to difficult emotions, improving cognitive flexibility, and facilitating the generation of alternative mental imagery that discourages self-harm.

Participants will receive either a single 5 mg dose of psilocybin or a placebo, followed by a cognitive behavioural therapy intervention. The trial will measure changes in self-harm-related mental imagery, emotional intensity, and cognitive belief patterns over a period of up to five months. Findings could provide valuable insights into novel treatment approaches for self-harm in young people.

Topic Depression
Compound Psilocybin
Country United Kingdom
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Imperial College London
The Centre for Psychedelic Research studies the action (in the brain) and clinical use of psychedelics, with a focus on depression.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.